Clinical Trial Update: Safety and Immunogenicity Study of tgAAC09, a Gag-PR-RT AAV HIV Vaccine [Phase 1]

View source ↗

Summary

The document reports the completion of a Phase 1 safety and immunogenicity study of tgAAC09, an AAV-based HIV vaccine targeting Gag-PR-RT.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• tgAAC09 (AAV-based HIV vaccine expressing Gag-PR-RT)

Snippet

Sponsor: International AIDS Vaccine Initiative | Conditions: HIV Infection | Phase 1 | Status: COMPLETED